ReadCoor is leading the next generation of omics by delivering the first panomic spatial sequencing platform to a global audience of researchers, clinicians, pharma and diagnostics companies, and ultimately patients. We are accomplishing this with Fluorescent in situ Sequencing (FISSEQ), a fundamental new technology which integrates high throughput sequencing, morphometric analysis, cellular location and three-dimensional spatial imaging. This uniquely powerful platform will revolutionize the next phase in understanding cellular and molecular biology, introducing vast new opportunities for important and meaningful clinical insight, and delivering swifter scientific discoveries, disease diagnosis and treatment development. 



Readouts that capture spatial data of cells and molecules provide researchers with the ability to create more robust cell atlases, identify new cells, and advance the study of cell growth and how cells and molecules interact. The ability of the FISSEQ platform to analyze samples across the entire panomic spectrum, from DNA to therapeutic molecules, ensures a comprehensive readout for swifter scientific discoveries. 

The Intelligence Advanced Research Projects Activity’s (IARPA) Machine Intelligence from Cortical Networks (MICrONS) research program is one of many scientific discovery efforts currently using FISSEQ. The project aims to advance the study of neural connections in the brain and reverse-engineer brain algorithms to enhance machine learning.




Robust reads from the FISSEQ platform can be leveraged to help researchers identify and differentiate healthy normal cells from diseased cell or foreign organisms. With this data scientists can better understand the progression of disease and the impact of foreign entities on a cell’s surrounding micro-environment.

In December 2016, ReadCoor received funding from the Bill & Melinda Gates Foundation to develop FISSEQ-based analytical tools to identify pathogens in tissue directly from their genomes and transcriptomes. Data from the diagnostic tools will be utilized to combat child mortality in developing countries.




Information distilled from scientific discoveries and diagnosis powered by the FISSEQ platform can be utilized to develop early intervention techniques and treatment options. The FISSEQ platform has the capability to analyze the pathway of drug candidates by determining if candidates meet their targets and improve treatment efficacy.  

Recently ReadCoor partnered with WAVE Life Sciences to advance the development of central nervous system therapeutic treatments. Researchers at ReadCoor are using FISSEQ to develop a mouse brain cell atlas that scientists at WAVE will use to characterize stereopure nucleic acid candidates in specific regions, cell types, and subcellular compartments of the brain.